National Cannabis Industry Association’s Post

#HFMA2024 taught us that #CFOs are hyper focused on three key areas, with #bigpharma tactics being one. Check out the rest from these top executives. https://lnkd.in/e-j6fhjx

A series of top #NewsReleases over the course of the last 14 days woke up some earlybirds & #SmartInvestors which led to a weekly #breakout (please see chart below) for Avicanna Inc. (TSX:AVCN) shares of its downtrend since Sept 2023. Next resistance would be a weekly close above 0,50 CAD which would offer a quick upside potential of another 60 % to reach the 0,80 CAD mark. As an #investor in #people and #megatrends we realized the potential of this #pearl in the #biopharma sector early and used the bottom building sideway range since early 2022 for building a strategic position. This sideway range is going to be broken out to the upside which will lead to substantial MCAP and price appreciation. Check out the news release today and just add 1+1 what it means for the the future growth and financial numbers for this SmallCap company. https://lnkd.in/dCYswRet #InvestmentCase #FamilyOffices #CommercialStage #VerticallyIntegrated and #Diversified #Biopharma #PlatformCompany

Today is the last day of the DiversifyRx #PharmacyProfitSummit in Dallas, Texas. Make sure to stop by to see our Assist Line and discover its many features! #MckessonPharmaAutomation #pps2024 #AutomatedSolutions #PharmacySolutions

✍ Reporting live from SCOPE 2024 ✍ Team Medrio is in Orlando this week for #SCOPE and caught a great session from Validcare CEO, Patrick McCarthy, Esq. about how small biopharma organizations need to remain close to their trial data and look for partners who share the same goals and convictions. According to Patrick, it’s important for small biopharma to choose a partner based on a “realistic flight plan,” not just an RFP, and to demand one unified data platform, real-time visibility, and control from their partners. What has been your SCOPE highlight so far?

Join Zoë Dunn on the Commercial and Marketing tracks at #REpharmaUSA today to discuss commercial strategy and precision marketing. #pharmamarketing

On today’s #BiotechHangout, hosts Brad Loncar, Michael Yee, Brian Skorney, CFA, Josh Schimmer and Tim Opler discuss the capital markets window & review the 4 IPOs & follow on activity this past week, Fed rate cut & #XBI jump, plus $ANI’s acquisition of $ALIM, a recap of significant developments from $MRNA vs $BNTX & the disparity in recent performance, $APLT’s regulatory update, $VNDA’s CRL, Express Scripts sues FTC over PBM report, a look at stock performances from $GILD (following Ph3 PrEP updates) & $DNLI (following FDA’s START pilot program), $JNJ’s TAR-200 Ph2 data, $FDMT wet AMD program update, Lasker award winners for GLP-1s & obesity work, and more. Join us: https://lnkd.in/eKdJkZWJ

Are you in the game? Make sure you have the strategies to win! Join us this Thursday and plan your next moves. Get your seat here: https://lnkd.in/gUFTCKpi You have a front row seat with this winning panel: Jeffrey Finkle Jeanne Mariani Sullivan Scott Greiper Chris Lindsey #cannabisindustry #cannabisbusiness #thoughtleaders #2024predictions #2024goals #insights #cannabisnews #cannabiseducation

Such a dynamic panel discussion including perspectives from Stuart McGahie, Philippe Guisset, Aswathi Padman and Niklas Mellerup, led by Anni Neumann, about how our experts are harnessing Next-Best-Action strategies to empower the field force #REpharma2024

@Polyscience President Philip Preston discusses evolving consumer expectations and the importance of longevity when choosing a temperature control solution. Listen to the full episode here https://loom.ly/u5_V6_0 #cannabiscommunity #cannabisindustry #MJBizCon2023 #cannatech

At AACR and would like to discuss building CRISPR models? Visit Travis Hardcastle and Alma Ines O., see details below #CRISPR #AACR #Editco #Drugdiscovery #cancerresesrch #IDEXX BioAnalytics!